All Stories

  1. β-Cell Secretory Capacity Predicts Metabolic Outcomes over 6 Years following Human Islet Transplantation
  2. Preservation of β-cell Function in Pancreatic Insufficient Cystic Fibrosis With Highly Effective CFTR Modulator Therapy
  3. Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)
  4. Autonomic dysfunction and risk of severe hypoglycemia among individuals with type 2 diabetes
  5. Long-term Outcomes With Islet-Alone and Islet-After-Kidney Transplantation for Type 1 Diabetes in the Clinical Islet Transplantation Consortium: The CIT-08 Study
  6. Factors associated with favourable 5 year outcomes in islet transplant alone recipients with type 1 diabetes complicated by severe hypoglycaemia in the Collaborative Islet Transplant Registry
  7. Evaluation of Clinical Metrics for Identifying Defective Physiologic Responses to Hypoglycemia in Long-Standing Type 1 Diabetes
  8. Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes
  9. Characterizing Glycemic Control and Sleep in Adults with Long-Standing Type 1 Diabetes and Hypoglycemia Unawareness Initiating Hybrid Closed Loop Insulin Delivery
  10. Pancreatic islet reserve in type 1 diabetes
  11. A tale of two pancreases: exocrine pathology and endocrine dysfunction
  12. High residual C-peptide likely contributes to glycemic control in type 1 diabetes
  13. Different β‐cell secretory phenotype in non‐obese compared to obese early type 2 diabetes
  14. Longitudinal Changes in Continuous Glucose Monitoring Use Among Individuals With Type 1 Diabetes: International Comparison in the German and Austrian DPV and U.S. T1D Exchange Registries
  15. The Transatlantic HbA 1c gap: differences in glycaemic control across the lifespan between people included in the US T1D Exchange Registry and those included in the German/Austrian DPV registry
  16. Advances in β-cell replacement therapy for the treatment of type 1 diabetes
  17. Biologic and social factors predict incident kidney disease in type 1 diabetes: Results from the T1D exchange clinic network
  18. Novel Preparations of Glucagon for the Prevention and Treatment of Hypoglycemia
  19. Cognitions Associated With Hypoglycemia Awareness Status and Severe Hypoglycemia Experience in Adults With Type 1 Diabetes
  20. Hypoglycemia‐associated autonomic failure, counterregulatory responses, and therapeutic options in type 1 diabetes
  21. Stem Cell–Derived Islets: Next Steps for Histologic and Functional Assessment During Development as a Cellular Therapy for the Treatment of Diabetes
  22. Noninvasive diagnosis of recurrent autoimmune type 1 diabetes after islet cell transplantation
  23. Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy
  24. Cheiroarthropathy: A Common Disorder in Patients in the T1D Exchange
  25. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016–2018
  26. Successful pregnancies after islet transplantation for type 1 diabetes
  27. Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions
  28. Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study
  29. Determinants of fracture in adults with type 1 diabetes in the USA: Results from the T1D Exchange Clinic Registry
  30. Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer
  31. First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes
  32. Metabolic network reconstruction and phenome analysis of the industrial microbe, Escherichia coli BL21(DE3)
  33. Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes
  34. Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells
  35. Contribution of parasympathetic muscarinic augmentation of insulin secretion to olanzapine-induced hyperinsulinemia
  36. Effects of GLP-1 and GIP on Insulin Secretion in Glucose Intolerant, Pancreatic Insufficient Cystic Fibrosis
  37. Marked Increases in CGM Use Has Not Prevented Increases in HbA1c Levels in Participants in the T1D Exchange (T1DX) Clinic Network
  38. Risk Factors for Adverse Kidney Disease Outcomes in Type 1 Diabetes (T1D)
  39. β-Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥155 mg/dL
  40. Mini-Dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes
  41. Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop
  42. Accuracy of Wrist-Worn Activity Monitors During Common Daily Physical Activities and Types of Structured Exercise: Evaluation Study (Preprint)
  43. Defining outcomes for beta cell replacement therapy: a work in progress
  44. Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial
  45. A randomized dose-response trial of aerobic exercise and health-related quality of life in colon cancer survivors
  46. Continuous Glucose Monitoring for Hypoglycemia Avoidance and Glucose Counterregulation in Long Standing Type 1 Diabetes
  47. Dose–response effects of exercise on insulin among colon cancer survivors
  48. Circulating B cells in type 1 diabetics exhibit fewer maturation-associated phenotypes
  49. Dose–response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial
  50. Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels
  51. Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults with Type 1 Diabetes
  52. Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer
  53. Tissue-specific exosome biomarkers for noninvasively monitoring immunologic rejection of transplanted tissue
  54. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes
  55. Centennial Celebration: Endocrine Reviews Past Highlights for November and December
  56. Autoimmune Diseases in Children and Adults With Type 1 Diabetes From the T1D Exchange Clinic Registry
  57. Long-Term Improvement in Glucose Control and Counterregulation by Islet Transplantation for Type 1 Diabetes
  58. Physiology-Invariant Meal Detection for Type 1 Diabetes
  59. Response to Comment on Rickels et al. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. Diabetes Care 2016;39:264–270
  60. Reduced β-Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance
  61. Executive Summary of IPITA-TTS Opinion Leaders Report on the Future of β-Cell Replacement
  62. Selective association of electrocardiographic abnormalities with insulin sensitivity and beta-cell function in type 2 diabetes mellitus: a cross-sectional analysis
  63. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia
  64. A randomized phase II dose–response exercise trial among colon cancer survivors: Purpose, study design, methods, and recruitment results
  65. Pancreas Transplantation in the Modern Era
  66. Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
  67. Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement
  68. Vascular Health Profile predicts cardiovascular outcomes in patients with diabetes
  69. Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study
  70. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes
  71. A Data-Driven Behavior Modeling and Analysis Framework for Diabetic Patients on Insulin Pumps
  72. Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics
  73. A Role for Transplant Endocrinologists - It's About Time
  74. Evidence-Informed Clinical Practice Recommendations for Treatment of Type 1 Diabetes Complicated by Problematic Hypoglycemia
  75. Activation of Innate Immunity Modulates Insulin Sensitivity, Glucose Effectiveness and Pancreatic β-Cell Function in Both African Ancestry and European Ancestry Healthy Humans
  76. Consistency of Quantitative Scores of Hypoglycemia Severity and Glycemic Lability and Comparison with Continuous Glucose Monitoring System Measures in Long-Standing Type 1 Diabetes
  77. Total Pancreatectomy With Islet Autotransplantation
  78. Restoration of Glucose Counterregulation by Islet Transplantation in Long-standing Type 1 Diabetes
  79. Islet Product Characteristics and Factors Related to Successful Human Islet Transplantation From the Collaborative Islet Transplant Registry (CITR) 1999–2010
  80. Total Pancreatectomy With Islet Autotransplantation
  81. Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides
  82. GLP-1 Plays a Limited Role in Improved Glycemia Shortly After Roux-en-Y Gastric Bypass: A Comparison With Intensive Lifestyle Modification
  83. Loss-of-Function Mutations in ABCA1 and Enhanced β-Cell Secretory Capacity in Young Adults
  84. Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
  85. Mutations in abca1 are associated with enhanced beta-cell secretory capacity in humans
  86. Insulin sensitivity index in type 1 diabetes and following human islet transplantation: comparison of the minimal model to euglycemic clamp measures
  87. Completion of the first FDA phase 3 multicenter trial of Islet transplantation in type 1 diabetes by the NIH CIT consortium
  88. Total pancreatectomy and islet autotransplantation in chronic pancreatitis: Recommendations from PancreasFest
  89. Differential Associations of Oral Glucose Tolerance Test–Derived Measures of Insulin Sensitivity and Pancreatic β-Cell Function With Coronary Artery Calcification and Microalbuminuria in Type 2 Diabetes
  90. Improvement in Insulin Sensitivity After Human Islet Transplantation for Type 1 Diabetes
  91. Antipsychotic-Induced Insulin Resistance and Postprandial Hormonal Dysregulation Independent of Weight Gain or Psychiatric Disease
  92. Severe Hypoglycemia and Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Results From the T1D Exchange Clinic Registry
  93. Improvement in β-Cell Secretory Capacity After Human Islet Transplantation According to the CIT07 Protocol
  94. Detection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: Recommendations from PancreasFest 2012
  95. Personalized cytomic assessment of vascular health: Evaluation of the vascular health profile in diabetes mellitus
  96. Case 33-2012: A Woman with Altered Mental Status after Childbirth
  97. Severe Insulin Resistance and Hypertriglyceridemia After Childhood Total Body Irradiation
  98. Raising Serum Gastrin to Improve Glycemic Control in (Type 2) Diabetes: Another Limb of the Enteroinsular Axis?
  99. Long Term Outcomes of Allogeneic Islet Transplantation: The Collaborative Islet Transplant Registry (CITR) 1999-2010
  100. Recovery of Endocrine Function After Islet and Pancreas Transplantation
  101. A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial
  102. Improvement in Outcomes of Clinical Islet Transplantation: 1999–2010
  103. Metabolic Function of a Suboptimal Transplanted Islet Mass in Nonhuman Primates on Rapamycin Monotherapy
  104. Early Metabolic Markers That Anticipate Loss of Insulin Independence in Type 1 Diabetic Islet Allograft Recipients
  105. HLA Class I Sensitization in Islet Transplant Recipients: Report from the Collaborative Islet Transplant Registry
  106. Accumulation of Intrahepatic Islet Amyloid in a Nonhuman Primate Transplant Model
  107. Hypersensitivity to Rabbit Antithymocyte Globulin in an Islet Transplant Recipient: A Case Report
  108. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose
  109. Changes in vitamin D binding protein and vitamin D concentrations associated with liver transplantation
  110. Amelioration of Hypoglycemia With Octreotide Therapy in Metastatic Insulinoma With Positive Octreotide Scan
  111. Analysis of B cell subsets following pancreatic islet cell transplantation in a patient with type 1 diabetes by cytometric fingerprinting
  112. Effects of metformin and leuprolide acetate on insulin resistance and testosterone levels in nondiabetic postmenopausal women: a randomized, placebo-controlled trial
  113. Fatal Malnutrition 6 Years After Gastric Bypass Surgery
  114. Proinsulin Processing and Transplanted Islets
  115. β-Cell Secretory Capacity and Demand in Recipients of Islet, Pancreas, and Kidney Transplants
  116. Experimental Endotoxemia Induces Adipose Inflammation and Insulin Resistance in Humans
  117. Narrative Review: Effect of Bariatric Surgery on Type 2 Diabetes Mellitus
  118. Exenatide Use in Islet Transplantation: Words of Caution
  119. Effect of Glucagon-Like Peptide-1 on β- and α-Cell Function in Isolated Islet and Whole Pancreas Transplant Recipients
  120. Amyloid and Transplanted Islets
  121. RS rearrangement frequency as a marker of receptor editing in lupus and type 1 diabetes
  122. Insulin Sensitivity, Food Intake, and Cravings with Premenstrual Syndrome: A Pilot Study
  123. Acute Insulin Responses to Glucose and Arginine as Predictors of β-Cell Secretory Capacity in Human Islet Transplantation
  124. Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on β-Cell Secretory Capacity
  125. Innate Immunity Modulates Adipokines in Humans
  126. Menstrual Cycle Effects on Insulin Sensitivity in Women with Type 1 Diabetes: A Pilot Study
  127. Glycemic Thresholds for Activation of Counterregulatory Hormone and Symptom Responses in Islet Transplant Recipients
  128. Calcific Uremic Arteriolopathy (Calciphylaxis)
  129. Insulin Sensitivity, Glucose Effectiveness, and Free Fatty Acid Dynamics after Human Islet Transplantation for Type 1 Diabetes
  130. Islet Cell Hormonal Responses to Hypoglycemia After Human Islet Transplantation for Type 1 Diabetes
  131. Impaired β-Cell Function in Type 1 Diabetes after Islet Transplantation
  132. Hypocalciuric Hypercalcemia and Autoantibodies against the Calcium-Sensing Receptor
  133. Hyperfunctioning Intrathyroidal Parathyroid Cyst
  134. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants